SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will report its fourth quarter 2021 financial results Tuesday, March 22, 2022, after market close. In conjunction with the release, management will host a conference call on Tuesday, March 22, 2022 at 1:30 p.m. PT / 4:30 p.m. EST to discuss the company’s recent financial results and highlights.
The press release and live audio webcast can be accessed via the Investors section of the Company’s website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409) 937-8880 (international) and referring to conference ID 9998693. Please dial in approximately 5-10 minutes prior to event to ensure a quick connection. . The archived webcast will remain available for replay on the Codex DNA website for 30 days.
About Codex DNA
Codex DNA gives scientists the ability to create sustainable synthetic biology solutions to many of humanity’s greatest challenges. As the inventor of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA enables fast, accurate and reproducible writing of DNA and mRNA for many downstream markets. The company’s award-winning BioXp™ system consolidates, automates and optimizes the entire synthesis, cloning and amplification workflow. As a result, it offers virtually error-free large-scale DNA/RNA synthesis in days and hours instead of weeks or months. Scientists around the world are using this technology in their own labs to accelerate the design-build-test paradigm of new, high-value products for precision medicine, biologic drug discovery, vaccine and therapeutics development, genome and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com. Contact: Richard Lepke Director of Investor Relations (619) 840-5392 RichardL@codexdna.com
Copyright 2022 GlobeNewswire, Inc.